Selinexor Approval, SCLC UpdateJune 29, 2020 | Oncology Hematology FDA Approves Selinexor for Relapsed/Refractory DLBCL The FDA granted selinexor (Xpovio, Karyopharm Therapeutics), a nuclear transport inhibitor, accelerated approval for this indication based on the response rate seen in the SADAL trial, a phase 2, single-arm, open-label study of patients with DLBCL who had previously received two to five systemic regimens. Read full article Internal Medicine First-Line Pembrolizumab Combo Improves PFS in Patients w. Extensive-Stage SCLC The Journal of Clinical Oncology published the double-blind, phase 3 KEYNOTE-604 clinical trial study results, which sought to compare pembrolizumab plus etoposide and platinum (EP) with placebo plus EP in treatment-naïve patients with ES-SCLC. Read full article Hematology Can Novel Drug Sensitivity Patterns for Informing Personalized Therapy in Myeloid Neoplasms Be Defined? This question is answered in Blood Advances, which features a visual abstract on how ex vivo drug screening was performed within a clinically actionable time frame (median 15 days) and predicted clinical responses in vivo. Read full article
DIET & NUTRITION 
PATIENT EDUCATION 
OBESITY/WEIGHT MANAGEMENT 
EXERCISE/TRAINING 
LEGAL MATTERS 
GUIDELINES/RECOMMENDATIONS